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Prostate cancer treatment has evolved
through the varying eras of therapy from
one of predominantly hormonal agents
without much effective cytotoxic therapy until the use of docetaxel was found
to improve overall survival in the pivotal TAX-327 (1) and SWOG 99-16 trials (2). While efforts to search for the
appropriate docetaxel partner has yielded
disappointing results with multiple Phase
III trials showing negative results, further
hormonal manipulation steadily gained
ground upon discovery of persistent hormonal signaling with the use of novel
androgen-biosynthesis inhibitors and antiandrogens. However, resistance to these
agents is ultimately inevitable. Increased
understanding of these resistance mechanisms may help re-channeling efforts
toward better refinement and improvement of drug therapies.
Prostate cancer remains the second
leading cause of death in the United States.
While treatment for early-stage low-risk
prostate cancer has been largely controversial with the advent of the prostate
specific antigen (PSA) screening controversy, treatment for metastatic castrationresistant prostate cancer (mCRPC) has
evolved with great strides in the past
decade, though remains incurable to this
day. Docetaxel as a treatment for mCRPC
brought about improvement in overall survival (1). To date, no appropriate docetaxel partner has been found to be beneficial. However, the utility of androgen
targeted signaling quickly gained ground
with the discovery of the relevance of
androgen receptor (AR) targeting long
after failure from androgen deprivation
therapy (3). This brought about the discovery and subsequent approval of both
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abiraterone acetate (4, 5) and enzalutamide (6, 7) in both the post-docetaxel
and pre-docetaxel space. While targeting androgen-signaling to date makes for
one of the most attractive approaches
in mCRPC therapy, several challenges
remain.
The AR is a 110-kDa steroid receptor encoded by the gene located in Xq1112 in the same family of nuclear hormone receptors as the estrogen, progesterone, and glucocorticoid receptors (8).
The AR functions as a “lineage oncogene”
of which prostate tumors become habitually addicted to (9). Conversely, several ARpathway genes are down-regulated upon
progression from a low-grade to highgrade prostate cancer or in the development of metastases (10). Despite targeting
the AR pathway using more contemporary
drugs with abiraterone or enzalutamide, it
is now increasingly recognized that resistance patterns are born at the cellular level,
with ligand independent AR activation, AR
mutation, intratumoral androgen synthesis, increased AR mRNA expression, and
AR maintenance by heat shock proteins
and AR structural alterations including
acquisition of splice variants all playing a
role in resistance (11). Given the inevitable
notion of resistance, efforts toward not just
sequencing, but combining these agents
offer exciting insights and opportunities
for treatment. For instance, TOK-001,
also known as galeterone, is a rationally
designed compound that has triple mechanism of action that includes inhibition of
CYP17A1 enzyme thereby blocking androgen synthesis, with preferential lyase over
hydroxylase inhibition, AR inhibition by
antagonizing testosterone binding to the
AR, which prevents binding of synthetic

androgens to both mutant and wild-type
AR, and finally, decreasing the amount of
AR through degradation of the AR protein. These unique mechanisms of action
are thought to be a possible promising
agent for the treatment of CRPC (12).
Thus, far, early Phase I testing (ARMOR 1)
demonstrating a minimal side effect profile has led to a Phase II trial (ARMOR
2) evaluating efficacy by means of PSA
response (NCT01709734). While TOK-001
and other promising drugs such as ARN509 are in the pipeline (13), there remains
a concern of whether the clinical trial endpoint that we are accustomed to that of
overall survival is the most appropriate
endpoint. To illustrate this point, results of
a lyase inhibitor TAK-700 or orteronel have
been presented in both the post-docetaxel
and pre-docetaxel setting. While the eligibility criteria and study design appears
comparable to contemporary clinical trials such as the COU-AA-301 and COUAA-302 as well as AFFIRM and PREVAIL
trials with abiraterone and enzalutamide,
respectively, the TAK-700 trials ELM-PC5
and ELM-PC4 were disappointingly negative. This raises a concern since this drug,
along with a multitude of other drugs, may
not necessarily be clinically inferior, but
increasingly difficult to prove superiority
or even equivalency given the landscape
of drugs currently approved that has been
shown to improve overall survival.
Addressing the issue of resistance is of
relevant importance given the notion that
all CRPC tumors will fail treatment eventually. Provocative findings show gain-offunction mutation in 3β-hydroxysteroid
dehydrogenase type 1 (3βHSD1) enzyme
that renders an alternative pathway to
resistance by inhibition of degradation
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and therefore provides a rapid route
of conversion of an adrenal-derived
dehydroepiandrosterone (DHEA) to the
more potent androgen dihydrotestosterone
(DHT), which can activate the AR (14).
Increasing observation also abounds with
regard to cross-resistance with novel
androgen-signaling inhibitors where less
than optimal responses are seen with enzalutamide post-abiraterone (15, 16) and
vice-versa (response with abiraterone postenzalutamide) (17). This phenomenon of
cross-resistance may also be seen with the
use of taxanes (18) with increasing recognition that taxanes inhibit AR translocation
with resultant inferior responses to docetaxel after abiraterone initiation (19). The
concurrent use of glucocorticoids has also
been touted as a possible mechanism of
resistance, especially in later stages of disease although this has been widely debated
(20). Identification of AR splice variants as
a mechanism of resistance may better predict the upfront resistance to the androgensignaling inhibitors, which may guide therapy as recently shown in lack of response
to either abiraterone or enzalutamide in
tumors harboring the AR-V7 splice variant
(21). In addition, better characterization of
genetic and chromosomal rearrangements
lends insights to potential targeting. For
instance, one of the most prevalent oncogenes expressed in prostate cancer is that of
ETS-related gene 1 (ERG) (22) and members of the ETS family of transcription factors (ERB, ETV1, ETV4) are placed under
the control of an androgen-regulated promoter that occurs in the transmembrane
protease, serine 2 (TMPRSS2), resulting in
a gene fusion TMPRSS2-ERG that occurs
in up to 50% of localized or metastatic
prostate cancer. This may be relevant with
addressing not only progression but also
averting resistance or determining drug
sequence patterns since response to abiraterone seem to be better in those who
harbor the gene fusion (23, 24). Another
interesting observation is the relationship
between this gene fusion with PTEN. An
invasive prostate cancer phenotype is promoted in phosphoinositide 3-kinase (PI3kinase) activation (25) or PTEN loss (26).
The cross-talk between PI3-kinase and
androgen-signaling (27) offers a pharmacologic opportunity to achieve dual inhibition of compensatory pathways to avert the
reciprocal feedback loop. Similar reciprocal
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relationship has been observed with androgen repression and c-met signaling with
resultant epithelial–mesenchymal transition (EMT) and stem-cell like phenotype.
In addition to the aforementioned genomic
aberrations, deletion in NKX3.1, amplification in C-Myc, deletion of p53, deletion
in CHD1, RB1, FOXA1, SPOP, and the
HSP70/HSP90 chaperone complex have all
been described (28, 29). Recently, a novel
approach to targeting the bromodomain
chromatin-binding protein BRD4, which
interacts with the N-terminal domain of
the AR using a small molecule JQ1, was
reported (30). While similar to enzalutamide in its ability to inhibit AR recruitment, it improves upon enzalutamide’s
action in its downstream AR binding, transcriptional regulation, and induction of
TMPRSS2-ERG gene oncogenic function.
In summary, much progress has been
made in the past decade alone in mCRPC
therapy, but a lot remains to be done to
further elucidate mechanisms of resistance
and to circumvent these resistance mechanisms. The AR remains to be a versatile
foe from progression of localized prostate
cancer to advanced and metastatic prostate
cancer and beyond castration-resistance.
Provocative findings of transcriptional regulatory pathways and methods of inhibiting them will usher in an exciting era of
targeting the AR in CRPC.
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